Cost-effectiveness of sotorasib as a second-line treatment for non-small cell lung cancer with KRASG12C mutation in China and the United States

• Egile Nagusiak: Ya-Ning Zhu (Egilea), Meng Tang (Egilea), Ke-Xin Sun (Egilea), Bei Gao (Egilea), Xian-Peng Shi (Egilea), Peng Zhang (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2024-06-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

PurposeTo evaluate the cost-effectiveness of sotorasib versus docetaxel in non-small cell lung cancer (NSCLC) patients with KRASG12C mutation from the China and United States'social perspective.Materials and MethodsA Markov model that included three states (progression-free survival, post-progr...